IVA News and Press, Inventiva S.A. From 03/16/24

2024-03-16 12:57:30 ET More on Madrigal Pharmaceuticals Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Ra...

2024-03-15 08:19:55 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...

2024-03-08 13:46:51 ET More on Inventiva Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause Inventiva drops after adverse event in Phase 3 trial for NASH drug Seeking Alpha’s Quant Rating on Inventiva Historical earnings data for ...

2024-02-22 16:50:41 ET Summary Enrollment pause in phase III NATiV3 study, using lanifibranor for the treatment of patients with NASH, only expected to last 4 to 6 weeks; Trial to continue on with protocol amendments. Publication of results from phase IIa LEGEND study, using lanif...

2024-02-16 13:52:08 ET More on Inventiva Inventiva reports 9M results Seeking Alpha’s Quant Rating on Inventiva Historical earnings data for Inventiva Financial information for Inventiva Read the full article on Seeking Alpha For furthe...

2024-02-16 10:00:07 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Communication Services, Info ...

2024-02-15 16:36:34 ET More on Inventiva Inventiva reports 9M results Seeking Alpha’s Quant Rating on Inventiva Historical earnings data for Inventiva Financial information for Inventiva Read the full article on Seeking Alpha For furthe...

2024-02-12 15:06:51 ET More on CymaBay, Gilead, etc. Gilead Sciences: Cheap For A Reason Gilead Sciences, Inc. (GILD) Q4 2023 Earnings Call Transcript Gilead Sciences, Inc. 2023 Q4 - Results - Earnings Call Presentation Gilead to acquire CymaBay for $32.50/sh...

2023-11-21 16:36:04 ET More on Inventiva Inventiva S.A. (IVA) Q2 2023 Earnings Analyst Call Transcript Inventiva and Hepalys Pharma to develop and commercialize Lanifibranor in Japan and South Korea Inventiva announced €35.7M funding, eyes future raise to meet...

2023-10-27 15:00:00 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...